Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... 14, 2014 During the 1600’s through the ... “The Doctor’s Plague.” In this time period, doctors did not ... at times, to the death of vulnerable patients. In the ... that they may be unwittingly transmitting herpes viruses to their ...
(Date:1/14/2014)... Triangle Park, NC (PRWEB) January 14, 2014 ... company focusing on ultra-sensitive POC diagnostic platforms and novel disease ... their first round of financing netting a total of $690,000. ... outside equity capital in the company. This group of private ...
(Date:1/14/2014)... City, Panama (PRWEB) January 14, 2014 ... has received the county’s first clinical trial approval ... umbilical cord-derived mesenchymal stem cells (MSC) from the ... Review Board (IRB). , Rheumatoid Arthritis (RA) is ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... SAN FRANCISCO, July 16 Nile Therapeutics, Inc. (Nasdaq: ... for heart failure patients, today announced that it has completed a ... purchase additional common stock for aggregate gross proceeds of approximately $3.4 ... the exclusive placement agent for the transaction. , ...
... , - Introductory Webinar, July 21st, 11am EDT, ... Meeting; September 15-16, San Diego,CA , ChemAxon, ... for Excel. The add-in for Microsoft Excel(R),brings all of the capabilities ... product will be introduced at a free webinar,on July 21st and ...
... /PRNewswire-FirstCall/ - avVaa World Health Care Products Inc. (Pink ... of nationally branded therapeutic, natural skin and health care ... design firm to design avVaa World Health Care,s product ... will include an up-to-date look and feel, customer friendly ...
Cached Biology Technology:Nile Therapeutics, Inc. Completes $3.4 Million Private Placement 2Nile Therapeutics, Inc. Completes $3.4 Million Private Placement 3ChemAxon Launches JChem for Excel 2avVaa World Health Care Products Inc. Announces Web Site Design for Neuroskin(R) Psoriasis Relief DRTV Campaign 2
(Date:4/17/2014)... This news release is available in German . ... fails to pay the protection money demanded of him, he ... are seldom required, however, as fear of the consequences is ... is observed in parasitic birds, which lay their eggs in ... egg out, the brood parasites take their revenge by destroying ...
(Date:4/17/2014)... a novel method to help kidney stone sufferers ... treatment possible., Kidney stones represent a major medical ... left untreated, apart from being particularly painful, they ... In many patients treated successfully, stone recurrence is ... approach to diagnosis and treatment needs to be ...
(Date:4/17/2014)... Researchers reporting in the Cell Press journal Current ... insects with rather novel sex lives. The Brazilian insects, ... genus Neotrogla , are the first example of ... reversal has been identified in several different animals, ... intromittent organ is also reversed," says Kazunori Yoshizawa from ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3In sex-reversed cave insects, females have the penises 2
... February 10, 2011 Promedior, Inc., a clinical ... and inflammatory diseases, announced today the publication of collaborative ... Cell Biology entitled, "TGF-beta driven lung fibrosis is ... The research showed that human Pentraxin-2 (PTX-2), also called ...
... from the Wildlife Conservation Society working in Kenya ... restricting fishing gear is producing more predatory and ... adjacent areas where no management is taking place. ... conservationists recording fish catches found that the implementation ...
... 2011 -- Research presented today at the 31st Annual meeting ... Meeting has found that three proteins known as XIAP, BID, ... progesterone treatments in the prevention of preterm labor. They ... The proteins prevent preterm birth by hindering ...
Cached Biology News:Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study 2Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study 3Kenya's fisheries management promotes species that grow larger and live longer 2Kenya's fisheries management promotes species that grow larger and live longer 3New research helps explain how progesterone prevents preterm birth 2
... Biochem/physiol Actions: Glutathione-S-transferases (GSTs) are a group ... many xenobiotics in mammals. The enzymes ... thiol group of the glutathione to electrophilic ... mutagenic, carcinogenic, and toxic effects of the ...
... Anti-GSTM1 Monoclonal Antibody Epitope: ... [Schistosoma japonicum]. Recommended Storage: ... Aliquot contents and freeze at -20 C ... of freezing and thawing. Centrifuge product if ...
... National Instruments PCIe-1429 is the industrys first ... PCIe-1429, you now can acquire images at ... available for Camera Link cameras to perform ... and image acquisition, fault analysis, and advanced ...
Amodiaquine...
Biology Products: